# Photys Therapeutics

Source: https://onco.cc/companies/photys-therapeutics/  
OnCo record `photys-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Photys Therapeutics builds two-headed molecules that bring a target protein next to an enzyme that modifies or destroys it. Its first clinical drug is for autoimmune disease; its cancer work, aimed at a mutant form of the p53 protein, is still in the laboratory.

## Summary

Photys Therapeutics is a Boston proximity-based therapeutics company with three heterobifunctional platforms: PROTAC degraders, PHICS (phosphorylation-inducing chimeric small molecules that recruit kinases to a target) and tPRIME (targeted proximity-induced modulators of expression). Its lead clinical programme, PHT-776/HPB-143, an oral IRAK4 PROTAC degrader licensed from Polymed in February 2025, entered phase 1 in August 2026 for autoimmune and inflammatory diseases. The oncology programme is preclinical: tPRIME bifunctionals directed at p53 Y220C, with data on p53-Y220C-BET bifunctionals driving cancer cell death presented in February 2025. A PHICS collaboration with Novo Nordisk (December 2024) covers cardiometabolic targets. Photys launched in September 2022 with a 75 million US dollar Series A led by MPM Capital, joined by Omega Funds, Longwood, 8VC, Eli Lilly and others.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Boston, MA
- Type: biotech
- Website: https://www.photys.com/

## Notes

- Oncology is a preclinical part of a mostly immunology and cardiometabolic pipeline. No SEC Form D filings were found under the company name. Founding year not sourced.

## Sources

- Official website: https://www.photys.com/
- Series A press release: https://www.photys.com/sep-08-2022-75million-series-a-funding-for-precision-phosphorylation

## Connected records

- fronts: [Drug Discovery Platforms](https://onco.cc/fronts/drug-discovery/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [TP53](https://onco.cc/targets/tp53/)
- companies: [Longwood Fund](https://onco.cc/companies/longwood-fund/), [MPM BioImpact](https://onco.cc/companies/mpm-bioimpact/), [Omega Funds](https://onco.cc/companies/omega-funds/)

---
JSON: https://onco.cc/api/v1/entities/photys-therapeutics.json